
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Antimicrobial Properties of 8-Hydroxyserrulat-14-en-19-oic Acid for
Treatment of Implant-Associated Infections
Justyna Nowakowska,a Hans J. Griesser,b Marcus Textor,c Regine Landmann,a Nina Khannaa
Laboratory of Infection Biology, Division of Infectious Diseases and Hospital Epidemiology, Department of Biomedicine, University Hospital Basel, Basel, Switzerlanda; Ian
Wark Research Institute, University of South Australia, Mawson Lakes, South Australia, Adelaide, Australiab; Department of Materials, ETH Zurich, Zürich, Switzerlandc
Treatment options are limited for implant-associated infections (IAI) that are mainly caused by biofilm-forming staphylococci.
We report here on the activity of the serrulatane compound 8-hydroxyserrulat-14-en-19-oic acid (EN4), a diterpene isolated
from the Australian plant Eremophila neglecta. EN4 elicited antimicrobial activity toward various Gram-positive bacteria but
not to Gram-negative bacteria. It showed a similar bactericidal effect against logarithmic-phase, stationary-phase, and adherent
Staphylococcus epidermidis, as well as against methicillin-susceptible and methicillin-resistant S. aureuswith MICs of 25 to 50
!g/ml andMBCs of 50 to 100!g/ml. The bactericidal activity of EN4 was similar against S. epidermidis and its"icamutant,
which is unable to produce polysaccharide intercellular adhesin-mediated biofilm. In time-kill studies, EN4 exhibited a rapid
and concentration-dependent killing of staphylococci, reducing bacterial counts by>3 log10 CFU/ml within 5 min at concentra-
tions of>50!g/ml. Investigation of the mode of action of EN4 revealed membranolytic properties and a general inhibition of
macromolecular biosynthesis, suggesting a multitarget activity. In vitro-tested cytotoxicity on eukaryotic cells was time and con-
centration dependent in the range of the MBCs. EN4 was then tested in a mouse tissue cage model, where it showed neither bac-
tericidal nor cytotoxic effects, indicating an inhibition of its activity. Inhibition assays revealed that this was caused by interac-
tions with albumin. Overall, these findings suggest that, upon structural changes, EN4might be a promising pharmacophore for
the development of new antimicrobials to treat IAI.
Implant-associated infections (IAI) are still a cause of high mor-bidity and social costs despite the substantial improvement of
early diagnosis and treatment. Optimal management of IAI re-
quires surgical intervention and use of antibiotics against adher-
ent bacteria (1). Staphylococci, including Staphylococcus aureus
(both methicillin-susceptible and methicillin-resistant strains)
and S. epidermidis, are the bacteria most frequently associated
with IAI (2). These bacteria are able to persist on the implant
surfaces, forming biofilms. Biofilms are multilayered communi-
ties of bacteria embedded in self-produced extracellular matrix
characterized by an oxygen and nutrient gradient throughout its
structure, inducing sessility in centrally situated cells (3, 4). The
biofilmmatrix is mainly composed of polysaccharide intercellular
adhesin (PIA), proteins and extracellular DNA (4). PIA produced
by ica operon-encoded enzymes has been implicated in the viru-
lence and immune evasion of S. epidermidis and the pathogenesis
of IAI (5).
Therefore, to successfully treat IAI, antimicrobials need to pen-
etrate the biofilm and act independently of the bacterial physio-
logical state. Thus far, most of the known antibiotics are depen-
dent on the metabolic status of bacteria hindering the eradication
of quiescent pathogens (6, 7). The only antibiotic with a proven
activity against staphylococcal biofilm is rifampin (8). However,
due to a rapid resistance development, it has to be combined with
other antibiotics. This and the recent increasing emergence of
drug-resistant bacteria highlight the need for new antimicrobials
to combat IAI.
An especially compelling approach is the investigation of anti-
microbials from natural sources. The large Australian plant genus
Eremophila (Myoporaceae), of which a few species have been tra-
ditionally used by Aborigines to treat various ailments (9), is na-
tive to arid areas of Australia and produces unique secondary me-
tabolites, among others nine classes of diterpenoids, including the
most commonly occurring serrulatanes (10). Screening of organic
extracts of Eremophila species revealed a selective effect against
Gram-positive bacteria (11).
The aim of the present study was to evaluate the activity in
vitro and in vivo and the mode of action of one of the com-
pounds extracted from leaves of Eremophila neglecta, 8-hy-
droxyserrulat-14-en-19-oic acid (EN4), as a new candidate for
the treatment of IAI.
MATERIALS AND METHODS
Antimicrobial agents, media, and chemical reagents. EN4was extracted
from freshly collected E. neglecta plant material with a purity of!95% (as
determined by nuclear magnetic resonance analysis) as described previ-
ously (12) and stored at !20°C. EN4 was dissolved in 1% dimethyl sul-
foxide (DMSO) (Merck, Darmstadt, Germany) in phosphate-buffered
saline (PBS) (Reagens, Basel, Switzerland) (DMSO-PBS) up to a concen-
tration of 400 "g/ml. Nisin (Sigma-Aldrich, Buchs, Switzerland) was sol-
ubilized in 0.02 M HCl. Daptomycin (DAP; Cubicin; Novartis, Bern,
Switzerland) was dissolved in 0.9% saline (Bichsel, Interlaken, Switzer-
land) supplemented with 50"g of calcium ions/ml (CaCl2). Actinomycin
D (Sigma-Aldrich), ciprofloxacin (Ciproxin; Bayer, Zürich, Switzerland),
vancomycin (Vancocin; Teva Pharma, Aesch, Switzerland), chloram-
phenicol (Applichem,Darmstadt, Germany), and chlorhexidine dihydro-
chloride (Sigma-Aldrich) were prepared according to the manufacturer’s
instructions. Bacterial media were purchased from Becton Dickinson
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(BD; Allschwil, Switzerland). 3H-labeled precursors of macromolecules
were obtained from Hartmann Analytic (Braunschweig, Germany). Un-
less otherwise stated, all chemical substances were purchased from Sigma-
Aldrich.
Microorganisms and growth conditions. The strains used in experi-
ments are listed in Table 1. Stocks ofmicroorganismswere prepared using
a cryovial bead preservation system (Microbank; Pro-Lab Diagnostics,
Richmond Hill, Ontario, Canada) and stored at!75°C. Unless otherwise
stated, for the preparation of overnight culture, a bead was incubated in 1
ml of tryptic soy broth (TSB) for 7 h at 37°C, diluted 1:100 in fresh TSB,
and incubated overnight at 37°C. For experiments with exponential-
phase bacteria, the overnight culture was diluted 1:100 and further incu-
bated for 5 to 6 h at 37°C, followed by two washes with 0.9% saline (Bich-
sel, Interlaken, Switzerland), and adjusted to an appropriate level of CFU/
ml. All cultures were prepared without shaking. CFU were determined
by plating of aliquots of 10-fold dilutions of bacterial cultures on
Mueller-Hinton agar (MHA), followed by 24 h of incubation at 37°C.
Susceptibility in vitro. (i) Gram-positive and -negative bacteria.The
minimal inhibitory and bactericidal concentrations (MIC and MBC, re-
spectively) of EN4 for logarithmically growing bacteria were determined
by using a macrodilutions method according to Clinical and Laboratory
Standards Institute guidelines (18).
For staphylococci, theMBCwas also assessed in the stationary growth
phase (MBCstat), which reflects themetabolic status of biofilm-embedded
microorganisms (24). MBCstat was determined using staphylococcal cul-
tures in nutrient-limited medium consisting of 0.1 to 0.25% TSB in PBS.
The use of this medium sustains bacterial counts within a range of 5" 0.5
log10 CFU/ml for at least 24 h. MBCstat was defined as the lowest concen-
tration of EN4 that reduced the inocula by!99.9% in 24 h.
(ii)Mycobacteria. Susceptibility ofMycobacterium tuberculosisATCC
27294 and ATCC 35838 to EN4 was determined bymicrowell alamarBlue
assay as previously described (19). Briefly, 0.5 McFarland inocula of M.
tuberculosis were diluted 1:25 in 2-fold concentrated medium (5.9 g of
Middlebrook 7H9 broth, 1.25 g of Bacto Casitone, 3.1 ml of glycerol, 100
ml of oleic acid-albumin-dextrose-catalase [OADC], 400 ml of distilled
water) and mixed with solutions of EN4 (final concentrations of 50, 100,
and 200 #g/ml) or 1%DMSO-PBS as untreated controls in a flat-bottom
96-well plate (BD). After 5 days of incubation at 37°C 30 #l of 0.01%
(wt/vol) resazurin (Sigma, St. Louis, MO) was added to untreated M.
tuberculosis, and the plate was reincubated for 24 h at 37°C. If the color
turned pink (indicating growth), resazurin was added to the rest of the
wells. The MIC was determined as the lowest concentration of EN4 pre-
venting color changes of resazurin (i.e., inhibiting growth ofM. tubercu-
losis) after 24 h of incubation at 37°C.
(iii) Candida. The susceptibility of Candida to EN4 was determined
according to CLSI guidelines (48). Five colonies of Candida were dis-
solved in 0.9% saline, and the turbidity adjusted to a 0.5 McFarland stan-
dard (1$ 106 to 5$ 106 CFU/ml). The suspension was diluted to 5$ 102
to 2.5$ 103 CFU/ml with RPMI 1640 (Gibco, Paisley, United Kingdom)
supplemented with 17.2 g of morpholinepropanesulfonic acid (MOPS)
and 10 g of glucose per 500 ml (pH 7.0). Then, 0.9 ml was transferred to
glass tubes containing 100 #l of 2-fold EN4 dilutions in 10% DMSO-
RPMI 1640. The tubes were incubated for 24 h at 35°C without shaking.
The MIC was determined as the lowest concentration of EN4 that inhib-
ited visible fungal growth.
Time-kill studies.Glass tubes containing TSBwith EN4 at concentra-
tions representing 0.5$ to 4$ the MIC were incubated with 106 CFU of
the test strain/ml at 37°C without shaking. Bacterial survival in the anti-
microbial-free culture containing 1%DMSO-PBS in TSB served as a con-
trol. At the indicated time points, aliquots were removed andwashedwith
0.9% saline to avoid potential drug carryover effect. The CFU were deter-
mined by plating aliquots of appropriate dilutions on MHA. A bacteri-
cidal effect was defined as a !3-log10 CFU/ml reduction in the initial
inoculum.
Susceptibility of adherent staphylococci in vitro. An exponential-
phase culture of the test strain was diluted in TSB supplemented with
0.5% glucose (BraunMedical AG, Sempach, Switzerland) to 104 CFU/ml.
A total of 100 #l was seeded in flat-bottom 96-well plates. After 18 h of
incubation at 37°C, the wells were washed and treated with 2-fold dilu-
tions of EN4 for 24 h at 37°C. The activity of EN4 against biofilm was
assessed by crystal violet (CV) staining as previously described (20).
Briefly, planktonic bacteria were discarded, and adherent bacteria were
washed. The plates were then incubated for 60 min at 60°C. Staining was
performed with 100 #l of 0.5% CV solution per well for 20 min at room
temperature, followed by a thorough washing under running tap water.
The bound CV was extracted with 100 #l of 33% acetic acid, and the
TABLE 1Microorganism strains used in this study
Species Straina Relevant properties Source or reference
Staphylococcus aureus Western Samoan Phage Pattern A
(WSPPA)*
MRSA ST30 13
ME230* MSSA, isogenic %SCCmecmutant of WSPPA M. Enderb
SA113 (ATCC 35556)† MSSA, production of PIA-mediated biofilm under aerobic
conditions
14
Staphylococcus epidermidis 1457‡ Efficient biofilm producer 17
1457 %ica‡ Isogenic %icamutant, devoid of PIA-mediated biofilm 17
Mycobacterium tuberculosis ATCC 27294 (H37Rv)§ Rifampin-sensitive strain 15
ATCC 35838 (H37Rv-RIF-R)‡ Rifampin-resistant strain
Streptococcus pyogenes ATCC 19615§ Laboratory strain isolated from human 16
Streptococcus pneumoniae TIGR4 (JNR.7/87) Encapsulated, virulent strain
Enterococcus faecalis ATCC 19433§ Laboratory strain
Pseudomonas aeruginosa PA01¶ Laboratory strain isolated from human
Escherichia coli ATCC 25922 Human clinical isolate
Candida albicans SC5314! Laboratory strain isolated from human
Candida glabrata t608919‡ Clinical isolate This study
Candida krusei ATCC 6258‡ Reference laboratory strain isolated from human
a Sources: *, B. Berger-Bächi, Zürich, Switzerland; †, F. Götz, Tübingen, Germany; ‡, D. Mack, Swansea, United Kingdom; §, R. Frei, Basel, Switzerland; ¶, U. Jenal, Basel,
Switzerland; !, S. Leibundgut-Landmann, Zürich, Switzerland.
b M. Ender, ETH Zürich, Switzerland (unpublished data).
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extracts were transferred to a fresh 96-well plate to be read. The optical
density of the samples wasmeasured at 590 nmusing aMolecular Devices
reader (Applied Biosystems, Rotkreuz, Switzerland). To determine the
effect of EN4 on bacterial viability, adherent bacteria were carefully de-
tached by pipetting up and down and then plated on MHA (21).
Macromolecular biosynthesis assay. Exponential-phase S. aureus
Western Samoan Phage Pattern A (WSPPA) was prepared in completely
defined medium (CDM) for peptidoglycan, RNA, and DNA or in CDM-
Leu for protein biosynthesis. CDM contained the following substances
per liter: 1.77 g of Na2HPO4, 1.36 g of KH2PO4, 0.2 g ofMgSO4·7H2O, 0.5
g of NH4Cl, 0.5 g of NaCl, 294.1 g of sodium citrate tribasic dehydrate, 1.5
g of glucose, 160 mg each of various amino acids (i.e., L-alanine, L-valine,
L-isoleucine, L-aspartic acid, L-glutamic acid, L-serine, L-threonine, L-cys-
teine hydrochloride, L-arginine, L-leucine, L-lysine, L-proline, L-phenyla-
lanine, L-tryptophan, and L-histidine monohydrochloride), 1.6 g of gly-
cine, 0.05 mg of cyanocobalamine, 0.04 mg of p-aminobenzoate, 0.01 mg
of biotin, 0.1 mg of nicotinic acid, 0.1 mg of D-pantotheic acid hemical-
cium salt, 0.15 mg of pyridoxine hydrochloride, 0.1 mg of thiamine hy-
drochloride, 0.1 mg of riboflavin, 69.5 !g of ZnCl2, 0.1 !g of
MnCl2·4H2O, 6 !g of BH3O3, 0.347 mg of CoCl2·6H2O, 2.6 !g of
CuCl2·2H2O, 24 !g of NiCl2·6H2O, 36 !g of NaMoO4·2H2O, 0.15 mg
of FeCl2·4H2O, 120mg of NaOH, 5mg of uracil, 5mg of cytosine, 5mg of
adenine, and 5 mg of guanine. The concentration of L-leucine in CDM-
Leu was 22.5 mg/liter instead of 160 mg/liter.
The culture (2 " 107 CFU/ml) was aliquoted into prewarmed glass
tubes and subsequently treated with 4" the MIC of EN4 (100 !g/ml),
vancomycin (8 !g/ml), actinomycin D (25 !g/ml), ciprofloxacin (8 !g/
ml), chloramphenicol (32 !g/ml), or chlorhexidine (CHX; 3.12 !g/ml),
followed by the immediate addition of 0.1!Ci [3H]N-acetylglucosamine/
ml, 1 !Ci of [3H]uridine/ml, 1 !Ci of [3H]thymidine/ml, or 3 !Ci of
[3H]leucine/ml to investigate the biosynthesis of peptidoglycan, RNA,
DNA, and proteins, respectively. Untreated control samples were exposed
to 1%DMSO-PBS. After 1 h of incubation at 37°C, 0.5-ml portions of the
bacterial suspensions were transferred to ultracentrifuge tubes and pre-
cipitated on ice with 1ml of ice-cold 10% trichloroacetic acid (TCA) for at
least 1.5 h. After this time, free fractions of precursors were removed from
the precipitates by washing with 5% TCA–1.5MNaCl and with 5% TCA.
Upon solubilization with 0.1% sodium dodecyl sulfate (SDS)–0.1
M NaOH, the precipitates were transferred to scintillation tubes
(Perkin-Elmer, Groningen, Netherlands) and thoroughly mixed with 2
ml of scintillation cocktail (Ultima Gold; Perkin-Elmer, Waltham, MA).
Radioactivity reflecting the amount of incorporated precursors was mea-
sured using a Tri-CARB 1900TR liquid scintillation analyzer (Packard,
Meriden, CT). Incorporation was measured in counts per minute (cpm)
and expressed as a percentage of the untreated control.
Flowcytometric analysis.Exponential-phase S. epidermidis 1457 (5"
107 CFU) was incubated for 10 min at 37°C with 100 !g of EN4 or CHX/
ml. Upon centrifugation, the samples were stained with 0.75 !M pro-
pidium iodide and 0.0625 !M SYTO9 from the Live/Dead BacLight bac-
terial viability kit (Invitrogen, Oregon). After 15 min of incubation at
room temperature protected from light, the green and red fluorescence
intensities of 105 stained bacteria per sample were recorded using a CyAn
ADP flow cytometer (Dako Cytomation, Glostrup, Denmark) and ana-
lyzed with FlowJo software (TreeStar, Stanford, CA).
ATP leakage assay. Exponential-phase WSPPA (7 " 108 CFU) was
exposed for 10min at 37°C to EN4 (50, 100, and 200!g/ml), CHX (50 and
100!g/ml), nisin (32!g/ml), ciprofloxacin (8!g/ml), or 1%DMSO-PBS
(untreated control). In order to assess ATP release, the bacteria were har-
vested by centrifugation, and 100 !l of each supernatant was transferred
to flat-bottom black-walled 96-well plate (Perkin-Elmer, Groningen,
Netherlands). ATP content was determined using the BacTiter-Glo assay
(Promega, Madison, WI). Luminescence was measured for 30 min with
SpectraMAX GeminiXS (Molecular Devices/Bucher Biotec, Basel, Swit-
zerland). The results are shown as the area under the curve.
Transmission electronmicroscopy. Exponential-phaseWSPPA (5"
109 CFU) was incubated for 1 h at 37°C with EN4 (100 and 200 !g/ml),
CHX (250 !g/ml), or 1% DMSO-PBS (untreated control) and harvested
by centrifugation. The pellets were resuspended in 2% glutaraldehyde in
PBS, followed by 2 h of fixation at room temperature. Postfixation was
carried out with reduced osmium tetroxide (1.5% KFeCN and 1% OsO4
in PBS) for 40min, followed by a second postfixationwith 1%OsO4 for 40
min. After a washing step, the bacteria were embedded in 2% agarose and
cut in blocks, which were dehydrated using 50, 70, 90, and 100% ethanol
(10 min each). The samples were further incubated in acetone (10 min).
Infiltration with Epon-acetone (50:50) for 1 h was followed by incubation
in pure Epon for 3 to 4 h. The samples were embedded in fresh Epon and
polymerized for 48 h at 60°C. Sections (60 nm) were cut at Ultracut E
(Leica), stained with 6% uranyl acetate, and analyzed using a Morgagni
transmission electron microscope (FEI).
EDTAcotreatment.The effect of EDTAon the susceptibility ofGram-
negative bacteria to EN4 and nisin was investigated as previously de-
scribed (22). Briefly, an overnight culture of P. aeruginosa PA01 was pre-
pared in brain heart infusion (BHI) broth, diluted 1:100 in fresh BHI
medium, and incubated at 37°C to a population density of 5" 107 CFU/
ml. Bacteria (5 " 105 CFU) were transferred to microcentrifuge tubes
containing buffer (50 mM Tris-HCl [pH 7.2]) supplemented with (i) 1
mM EDTA, (ii) 5 mM EDTA, (iii) 100 !g of nisin/ml, (iv) 100 !g of
nisin/ml and 1 mM EDTA, (v) 200 !g of EN4/ml, or (vi) 200 !g of
EN4/ml and 5 mM EDTA. The samples were incubated for 1 h at 37°C.
The numbers of surviving bacteria were determined by plating aliquots
on MHA.
Cytotoxicity on eukaryotic cells. The cytotoxicity assay was prepared
as previously described (20). Briefly, mouse L929 fibroblasts were cul-
tured in complete RPMI 1640 supplemented with 5% heat-inactivated
fetal bovine serum (FBS). To assess the cytotoxicity of EN4 over time, 104
cells/well were seeded in a flat-bottom 96-well plate in RPMI 1640 sup-
plemented with 3.75% FBS, followed by incubation for 4 h until the fibro-
blasts adhered. After this time, EN4 solutions in 3.75% FBS-RPMI were
transferred to wells to final concentrations of 25, 50, and 100 !g/ml.
Fibroblasts incubated with 1% DMSO-PBS instead of EN4 served as an
untreated control. At the indicated time points, the activity of the lactate
dehydrogenase (LDH) was assessed in cell supernatants and correspond-
ing lysates (total LDH) using the CytoTox 96 nonradioactive cytotoxicity
assay (Promega) according to the manufacturer’s instructions. Cytotox-
icity was defined as LDH release and was expressed as a percentage of the
total LDH.
For determination of the influence of FBS on the cytotoxicity of EN4,
fibroblasts were seeded and treated with EN4 at 100 !g/ml in RPMI sup-
plemented with 3.75, 5, or 10% FBS, and then the cytotoxicity was as-
sessed as described above.
Activity in vivo. The in vivo activity of EN4 against S. aureus SA113
was investigated in a mouse model of foreign body infection as described
previously (21) with the approval of the Kantonale Veterinaeramt Basel-
Stadt (permit 1710). Experiments were conducted according to the regu-
lations of Swiss veterinary law. Female C57BL/6 mice (Harlan Laborato-
ries, Switzerland), 9 to 11 weeks old, kept under specific-pathogen-free
conditions in the animal house of the Department of Biomedicine, Uni-
versity Hospital Basel, were anesthetized via intraperitoneal injection of
65 mg of ketamine (Ketalar; Pfizer, Zürich, Switzerland)/kg and 13 mg of
xylazinum (Xylasol; Graeub, Bern, Switzerland)/kg, followed by the sub-
cutaneous implantation of sterile Teflon tissue cages (Angst# Pfister AG,
Zürich, Switzerland). After surgery, themice were treated with 0.05mg of
buprenorphine (Temgesic; Essex Chemie, Lucerne, Switzerland)/kg to
treat postoperative pain. Upon complete wound healing (2 weeks), the
mice were anesthetized with isoflurane (Isofuran; Abbott, Wiesbaden,
Germany), and the cages were tested for sterility by plating percutane-
ously aspirated tissue cage fluid (TCF) on Columbia sheep blood agar
plates. To simulate a perioperative infection, the cages were injected with
100 and 250 !g of EN4 (10 mice per group) or 30 !g of DAP (5 mice per
New Antimicrobial for Implant-Associated Infections
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group) and then immediately infected with 4 ! 103 CFU of SA113. Un-
treated control cages were injected with 1% DMSO-PBS (8 mice per
group). After 24 and 48 h, the TCFwas collected into ultracentrifuge tubes
containing 10"l of 1.5%EDTA in 0.45% saline (pH 7.3) to avoid clotting,
and the cageswere reinjectedwith the respective substances. TCFwas used
to determine the numbers of planktonic SA113 by plating appropriate
dilutions on blood agar plates and to assess the viability of leukocytes by
trypan blue staining. Aspiration of TCF was repeated after 72 h, and the
mice were sacrificed. Tissue cages were explanted under aseptic condi-
tions, washed twice with 0.9% saline in order to remove planktonic bac-
teria, and cultured in TSB. The cages were vortexed at 0, 24, and 48 h to
increase the possible regrowth of adherent bacteria. After 48 h of incuba-
tion at 37°C, the bacterial presence in the cultures was determined by
plating onblood agar plates.Detection of the growth of SA113was defined
as treatment failure. The efficacy of treatment against adherent bacteria
was expressed as the cure rate, defined as the percentage of cages without
growth in the individual treatment group.
Inhibition of EN4 activity. An overnight culture of SA113 was trans-
ferred to glass tubes (2 ! 106 CFU/ml) containing TSB supplemented
with EN4 (100 "g/ml) in the presence of mouse TCF (2.5, 5, and 75%),
pooled normal human serum (NHS; 1.25, 2.5, and 75%), human serum
albumin (HSA; Blutspendedienst SRK, Bern, Switzerland) (0.125 and
0.25%), or 300 "g of human fibrinogen (Hyphen BioMed, Allschwil,
Switzerland)/ml (representing 10% of the normal blood level). The sam-
ples were incubated for 6 h at 37°C. Then, 0.5-ml portions of the suspen-
sions were transferred to microcentrifuge tubes and washed once with
0.9% saline, and the numbers of surviving bacteria were determined by
plating. The results were calculated as the log10 CFU/ml reduction from
the initial inoculum. None of the supplements influenced the viability of
SA113 in the absence of EN4 (data not shown).
Statistical analysis.Data were analyzed by GraphPad Prism 5.0a pro-
gram (GraphPad Software). The Mann-Whitney U test or one-way anal-
ysis of variance (ANOVA) were used to determine the statistical signifi-
cance (P) of differences in the in vitro assays. The statistical tests used for
each experiment are specified in the figure legends.
RESULTS
EN4 acts in a rapid and dose-dependent manner against Gram-
positive bacteria in vitro. The MICs and MBCs of EN4 were
determined for different strains of Gram-positive and Gram-neg-
ative bacteria, as well as for M. tuberculosis and Candida species.
The results are summarized in Table 2 and Table 3. Both Strepto-
coccus pyogenes and Streptococcus pneumoniae showed the highest
susceptibility to EN4, withMICs of 6.25 and 1.6"g/ml andMBCs
of 12.5 and 3.12 "g/ml, respectively. The MIC and MBC of EN4
for Enterococcus faecalis were both 50 "g/ml. As previously re-
ported (12), Gram-negative bacteria were not susceptible to EN4
at concentrations up to 200 "g/ml. Interestingly, EN4 was active
against rifampin-susceptible and -resistantM. tuberculosiswith an
MICof 100"g/ml.C. albicanswas not influenced by EN4,whereas
C. glabrata andC. kruseiwere susceptible with an EN4MIC of 200
"g/ml, the highest concentration used. EN4 showed a bactericidal
effect against various logarithmic-phase staphylococci. The
MIClog values for S. epidermidis 1457 and its isogenic, biofilm-
deficient#icamutant were 25 and 50"g/ml, respectively, and the
MBClog was 100 "g/ml. EN4 was similarly active against MRSA
strain WSPPA and its isogenic, methicillin-susceptible mutant
ME230 with an MIClog of 25 "g/ml and an MBClog of 50 "g/ml.
SA113 capable of producing PIA-mediated biofilm under aerobic
conditions was susceptible to EN4, with anMIClog and anMBClog
of 25 and 50 "g/ml, respectively.
To investigate whether EN4 could be used to treat IAI, further
experiments were focused selectively on staphylococci. In time-
kill studies EN4 showed a dose-dependent activity againstWSPPA
with a bactericidal effect (!3-log10 CFU/ml reduction) within 5
min at MBClog (Fig. 1). Similar kinetics was observed for other
staphylococci (data not shown). This is in line with previous find-
ings indicating that Eremophila duttoni extract eradicated MRSA
within 1 h (23).
Taken together, these results show that EN4 acts specifically
against a range of Gram-positive bacteria andM. tuberculosiswith
a rapid and dose-dependent kinetics for staphylococci.
TABLE 2 In vitro susceptibility of Gram-positive and Gram-negative




Streptococcus pyogenes ATCC 19615 6.25 12.5
Streptococcus pneumoniae TIGR4 (ATCC BAA-334) 1.6 3.12
Enterococcus faecalis ATCC 19433 50 50
Pseudomonas aeruginosa PA01 $200 $200
Escherichia coli ATCC 25922 $200 $200
Mycobacterium tuberculosis ATCC 27294 100 –a
ATCC 35838 100
Candida albicans SC5314 $200
Candida glabrata t608919 200
Candida krusei ATCC 6258 200
a Susceptibility was determined only as the MIC.
TABLE 3 In vitro susceptibility to EN4 of staphylococci in the





Staphylococcus aureus MRSAWSPPA 25 50 100
MSSA ME230 25 50 100
MSSA SA113 25 50 50
Staphylococcus epidermidis 1457 25 100 100
1457 #ica 50 100 100
FIG 1 Time-kill studies ofWSPPA exposed to titrated concentrations of EN4.
Dotted line represents a bactericidal effect, i.e., a 3-log10 CFU/ml reduction
from the initial inoculum. The values shown are means of three independent
experiments% the standard deviations (SDs).
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EN4 acts against staphylococci independently of growth
phase andPIA-mediatedbiofilm. IAI aremainly caused by staph-
ylococci growing in biofilms. Therefore, the effect of EN4 on
staphylococci in the stationary growth phase, which is believed to
reflect the status of biofilm-embedded bacteria (24), was studied.
Interestingly, the transition from the logarithmic to the stationary
growth phase did not decrease bacterial susceptibility to EN4,
as evidenced by comparable MBC values for logarithmically
(MBClog) and stationary (MBCstat) growing staphylococci (Table
3). Next, the impact of EN4 on biofilm was investigated using CV
staining. EN4 at concentrations of !25 !g/ml significantly de-
creased an abundant biofilm of S. epidermidis 1457 (Fig. 2). The S.
epidermidis 1457 "ica mutant deficient in PIA used as a control
gave an overall lowCV signal that was not influenced by EN4 (Fig.
2). Since CV does not distinguish between live and dead bacteria
due to its affinity to the negatively chargedmolecules present both
at the bacterial surface and in the biofilmmatrix (25), the viability
of adherent staphylococci was additionally assessed. Of note, the
bactericidal activity of EN4 on S. epidermidis 1457 and its "ica
mutant was similar. Treatment with EN4 at!100 !g/ml resulted
in 3-log10 CFU/ml reduction of adherent bacteria for both strains
(Fig. 2B). Similar results were obtained for other staphylococci
(WSPPA, ME230, and SA113; data not shown).
These results show that EN4 is similarly active against staphy-
lococci in the logarithmic and stationary growth phases, as well as
embedded in PIA-mediated biofilm, making it promising for the
treatment of IAI.
EN4 inhibits synthesis of DNA, RNA, protein, and pepti-
doglycan. To understand the mechanism of action of EN4, mac-
romolecular biosynthesis assays were performed. The incorpora-
tion of 3H-labeled precursors of peptidoglycan, RNA, DNA, and
proteins by WSPPA was assessed in the presence of EN4, control
antibiotics, and the antiseptic CHX at 4# the MIC. The control
antibiotics vancomycin, actinomycin D, ciprofloxacin, and chlor-
amphenicol reduced biosynthesis of their specific targets, pepti-
doglycan, RNA, DNA, and proteins, respectively (Fig. 3). More-
over, actinomycin D consequently reduced also the production of
DNA and proteins. In contrast, EN4 inhibited all biosynthetic
pathways. This was comparable to themode of action of CHX and
points toward a multitarget antiseptic rather than an antibiotic
mechanism of action of EN4.
EN4 affects bacterial membrane integrity causing ATP leak-
age. To further reveal the mechanism of action of EN4, its effect
on bacterial membrane integrity was studied. Flow cytometric
analysis with propidium iodide and SYTO9 staining showed that
the membrane integrity of S. epidermidis 1457 was similarly af-
fected by treatment with bactericidal concentrations of EN4 and
CHX (Fig. 4A). This is in agreement with a previous report on
membranolytic properties of the extract of Eremophila duttoni
leaves, which also contain active serrulatanes (26). Exposure to
EN4 and CHX also led to ultrastructural changes of WSPPA, as
shown by transmission electron microscopy. Membrane invagi-
FIG 2 Effect of EN4 on adherent S. epidermidis 1457 and its "ica mutant.
Inocula of both strains (103 CFU/well in 96-well plates) were incubated for 18
h at 37°C, followed by the addition of EN4 at titrated concentrations. After 24
h of exposure, the influence of EN4 on the biofilm and the viability of staph-
ylococci was determined by CV staining (A) and plating of detached bacteria
(B), respectively. The values shown are means of three independent experi-
ments prepared in triplicates$ the SDs. Significant CV signal reduction for S.
epidermidis 1457 compared to results for the untreated control is indicated
(*, P % 0.05 [Mann-Whitney U test]). In panel B, dotted lines represent a
3-log10 CFU/ml reduction in S. epidermidis 1457 (}) and "ica (!) from
untreated samples.
FIG 3 Inhibition of biosynthesis of macromolecules by EN4. The incorporation of [3H]N-acetylglucosamine (A), [3H]uridine (B), [3H]thymidine (C), and
[3H]leucine (D) byWSPPA treated for 1 hwith EN4, vancomycin (VAN), actinomycinD (ActD), ciprofloxacin (CIP), chloramphenicol (CHL), or chlorhexidine
(CHX) at 4# the MIC was expressed as the percentage of untreated control (peptidoglycan, 3,444$ 1,212 cpm; RNA, 115,538$ 19,533 cpm; DNA, 13,862$
762 cpm; protein, 7,065 $ 323 cpm). The values shown are means of at least two independent experiments prepared in duplicates $ the SDs. Dotted lines
represent 100% incorporation. Significant reduction of biosynthesis compared to results for the untreated control is indicated (*, P% 0.05; **, P% 0.01; ***,
P% 0.001 as determined by one-way ANOVA [Kruskal-Wallis test]) with a Dunn post test).
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nation and mesosome-like structures were observed after EN4
treatment; such features were previously attributed to membra-
nolytic activity (27) (Fig. 4B). CHX mostly affected the bacterial
cytoplasm causing formation of multiple intracellular granules,
which possibly mirrored precipitation of cytoplasmic molecules
(28).
To elucidate the physiological consequences of membrane dis-
integration, ATP leakage fromWSPPA was measured. The results
indicate that themembrane disruption by EN4 is accompanied by
a concentration-dependent ATP leakage (Fig. 4C). The release of
ATP was also observed for CHX and nisin, known for their mem-
brane activity, but not for ciprofloxacin, in accordance with its
intracellularmode of action onDNAgyrase and topoisomerase IV
(29). Hence, EN4 was found to affect membrane integrity and to
cause ATP leakage.
The tolerance of Gram-negative bacteria to EN4 can be re-
versed by destabilization of the outermembrane. Since the find-
ings thus far point toward a multitarget mode of action, we won-
dered why EN4 selectively acts against Gram-positive bacteria.
One of the causes of higher antibiotic tolerance of Gram-negative
bacteria is the presence of the outer membrane, which poses an
efficient permeability barrier. This barrier, however, can be
breached by EDTA (30). EDTA chelates Ca2! and Mg2! that are
involved in noncovalent binding of lipopolysaccharidemolecules,
and treatment with EDTA results in an increased permeability of
the outer membrane (30). The induced susceptibility of Gram-
negative bacteria to antibiotic/EDTA cotreatment has been re-
ported for many antimicrobials, such as nisin (22). Therefore, to
assess whether the outer membrane of Gram-negative bacteria is
responsible for the lack of susceptibility to EN4, P. aeruginosa
PA01 was exposed to EN4 and EDTA. Nisin was used as a control
(Fig. 5). EDTA induced the activity of EN4 against P. aeruginosa
PA01 up to a bactericidal level. Similar results were obtained for
nisin. This effect was observed to a lesser extent for E. coli ATCC
25922 (data not shown), which can be explained by the fact that
the impermeability of the E. coli membrane is less dependent on
divalent cations (31). Thus, the tolerance of Gram-negative bac-
teria to EN4 is mediated by the outer membrane and can be re-
versed in the presence of EDTA.
EN4 induces the cytotoxicity of eukaryotic cells in vitro in a
dose- and time-dependent manner. The cytotoxicity of an anti-
microbial compound indicating the adverse potential is impor-
tant if the compound is to be used to prevent or treat IAI. There-
fore, we quantified the cytotoxicity of EN4 on eukaryotic cells by
LDH release. EN4 at 25"g/ml corresponding toMICs of S. aureus
did not affect the viability of mouse L929 fibroblasts (Fig. 6). Cy-
totoxicity was observed within the range of MBCs and was time
dependent. After 8 h of exposure to EN4 at 50"g/ml, the cytotox-
icity reached 50%, whereas 1 h to 2 h of contact with EN4 at 100
"g/ml had already resulted in a cytotoxicity of ca. 100%. These
FIG 4 Effect of EN4 on bacterial membrane integrity. (A) S. epidermidis 1457 was incubated for 10 min with EN4 or CHX at 100 "g/ml or 1% DMSO-PBS and
subsequently double stained with propidium iodide (PI) and SYTO9 and analyzed by flow cytometry. The results of one representative experiment of three
performed are shown. (B) Transmission electronmicroscopy images of ultrathin sections ofWSPPA treated for 1 h with 1%DMSO-PBS as a control, EN4 at 100
or 200 "g/ml, or 250 "g of CHX/ml. Arrowheads indicate ultrastructural changes; the bars represent 200 nm. (C) WSPPA was treated for 10 min with EN4 or
CHX at 100"g/ml, followed by centrifugation and investigation of supernatants for the presence of ATP using luciferase reaction. Nisin (NIS) and ciprofloxacin
(CIP) were used as a positive and a negative control, respectively, and 1% DMSO-PBS was used as an untreated control (Ctrl). The values shown are means#
the SDs of areas under the concentration-time curve calculated for the first 30 min of luciferase reaction from at least three independent experiments prepared
in duplicates. Significant ATP leakage compared to results for the untreated control is indicated (*, P$ 0.05; **, P$ 0.01 as determined by one-way ANOVA
[Kruskal-Wallis test] with a Dunn post test).
FIG 5 Effect of EN4-EDTA cotreatment on P. aeruginosa PA01. P. aeruginosa
PA01 (106 CFU/ml) was incubated for 1 h in the presence of 200"g of EN4/ml
with or without 5 mMEDTA. Bacteria treated with 100"g of nisin/ml with or
without 1mMEDTA served as control. The results were calculated as the log10
CFU/ml differences between initial and final numbers of bacteria. The dotted
line represents a 3-log10 CFU/ml reduction from the initial inoculum. The
values shown are means of three independent experiments# the SDs.
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results indicate that mouse fibroblasts and staphylococci are sim-
ilarly susceptible to EN4 and that EN4 therefore has a small ther-
apeutic window in vitro.
EN4 exhibits neither antimicrobial nor cytotoxic activity in
vivo. Since EN4 showed favorable in vitro activity against biofilm-
forming staphylococci but concomitantly was cytotoxic on eu-
karyotic cells, we performed in vivo studies to test its efficacy in a
previously established tissue cage model in mice. Tissue cages
were infected with 4! 103 CFU of SA113, an inoculum mimick-
ing a perioperative infection. Injection of 4! and 10! theMICs of
EN4 or 30 "g of DAP per cage was followed by an immediate
infection to check whether EN4 is able to prevent bacterial adhe-
sion and consequently clears the infection. EN4 did not decrease
the number of planktonic bacteria in the TCF (Fig. 7A), whereas
30"g of DAP per cage reduced the number of planktonic bacteria
by #2 log10 CFU/ml, as previously reported (32). Reinjection of
EN4 at days 1 and 2 did not improve its antimicrobial effect, as
opposed to DAP that cleared planktonic bacteria in 80 and 60%
cages at days 2 and 3, respectively. The cure rate that corresponds
to the regrowth of adherent SA113 from explanted cages was 0%
for all cages (data not shown). This indicates a failure of EN4 and
also, as previously described (32), of DAP in the eradication of
adherent bacteria in vivo. In addition, the viability of leukocytes
present in TCF was not affected by EN4 (Fig. 7B). In summary,
despite its in vitro satisfactory activity, EN4 did not exhibit any
antibacterial or cytotoxic properties in vivo, indicating an inhibi-
tion of its activity.
The activity of EN4 is inhibited by interactionwith albumin.
Pharmacokinetic and pharmacodynamic studies revealed that the
in vivo efficacy of drugs strongly depends on their interactions
with plasma proteins and lipids. These interactions allow a pro-
longed activity but may also decrease the treatment efficacy (33).
Therefore, to elucidate whether interactions with proteins play a
role in the inhibition of EN4 observed in vivo, the survival of
SA113 was determined in the presence of EN4 at 100 "g/ml and
various physiological fluids and proteins. TCF andNHSdecreased
the antibacterial activity of EN4 in a concentration-dependent
manner. Similar levels of inhibition were observed for 5% TCF
and for 2.5% NHS, in agreement with previous findings that TCF
contains around half of the amount of proteins present in serum
(34). Both TCF and NHS at 75% resulted in complete inhibition
of EN4 (Fig. 8A). Furthermore, a similar effect was observed for
HSA at 0.25%, but not for fibrinogen, indicating that binding to
albumin is responsible for the inhibition of EN4. Under the same
conditions, ciprofloxacin, which is bound by plasma proteins up
to 28% (35), was not inhibited, and at a concentration of 4! the
MIC reduced the number of SA113 by 3 log10 CFU/ml (data not
shown).
Consequently, to assess whether the eukaryotic cytotoxicity of
EN4, which is observed in vitro but not in vivo, is influenced by
albumin, mouse L929 fibroblasts were exposed to EN4 at 100
"g/ml in the presence of titrated concentrations of FBS, and the
cytotoxic effect was measured. Whereas EN4 at 100 "g/ml in the
presence of 3.75% FBS, which was used in the previous cytotoxic-
ity experiment, induced rapid cell death, this effect was completely
abolished by 10% FBS (Fig. 8B). These findings indicate that the
activity of EN4 is inhibited in vivo by interactions with albumin.
DISCUSSION
Over the past several decades, antibiotic pressure has induced se-
lection for resistant bacteria to every clinically used antibiotic. In
the search for new antibacterial drugs, natural products derived
from traditional medicinal plants are currently used as scaffolds
for drug development.
The aim of the present study was to investigate EN4, a new
antimicrobial compound extracted from Eremophila neglecta.
EN4 belongs to a class of derivatives of diterpenes, one of the
largest plant-derived families of secondary metabolites with anti-
staphylococcal activity (36). Due to this activity, the underlying
premise of the present study was the potential use of EN4 in the
FIG 6 Cytotoxicity of EN4 onmouse L929 fibroblasts. L929 cells were treated
with EN4 at antistaphylococcal concentrations, and the cytotoxic effect was
assessed over time by measuring the released lactate dehydrogenase (LDH).
The results are expressed as the percentage of total LDH obtained from com-
pletely lysed cells. The values shown are means of at least three independent
experiments prepared in triplicates $ the SDs. The dotted lines represent
inhibitory concentrations of EN4 causing the death of 50 or 90% of cells (IC50
and IC90, respectively).
FIG 7 In vivo activity of EN4 in a mouse tissue cage model. The numbers of
planktonic SA113 (A) and the viability of leukocytes (B) present in tissue cage
fluid from cages treated with 100 or 250 "g of EN4 or 30 "g of daptomycin
(DAP) and infectedwith 4! 103CFUof SA113were investigated.Open circles
indicate control mice injected with 1% DMSO-PBS. The values shown are
means$ the SDs.
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prophylaxis or treatment of IAI. This is, to our knowledge, the first
detailed report on an antistaphylococcal activity and the mode of
action of an active compound purified from an extract from Er-
emophila plant species.
The activity of EN4 was investigated primarily against staphy-
lococci, since these organisms are the main cause of IAI (2). EN4
showed a rapid, dose-dependent bactericidal effect on logarithmi-
cally growing staphylococci regardless of methicillin resistance.
Furthermore, its activity was not affected by transition of staphy-
lococci to the stationary phase. This is of great advantage for the
treatment of IAI since agents bactericidal for logarithmically
growing pathogens may fail to act on slow-growing or nongrow-
ing bacterial populations (37).
Chronic infections with biofilms, such as IAI, pose a challenge
for antimicrobials. To date, the only antibiotic with proven in vivo
activity against staphylococcal biofilm is rifampin, which due to a
rapid resistance development has to be used in combination ther-
apy for IAI (8). In this context, EN4 reduced biofilm of S. epider-
midis 1457 by !3 log10 CFU/ml in vitro, irrespective of PIA. The
mechanism of its antibiofilm activity might be an efficient pene-
tration of the biofilmmatrix, which allows accessing and exerting
growth-phase-independent properties against sessile bacteria.
This is in contrast to DAP. Its activity is decreased against station-
ary-phase S. aureus and biofilm in vivo and in vitro (21, 32) despite
its ability to penetrate the biofilm structure (38). Recent results on
antibiotics such as telavancin (39) or oritavancin (40) have dem-
onstrated activity in vitro against stationary-phase bacteria or bio-
films; however, they still require in vivo evaluation. These in vitro
properties make EN4 a promising compound despite its elevated
MIC andMBC values that are often found for plant-derived prod-
ucts. Indeed, it has been suggested, due to the lack of antimicro-
bials active against nongrowing bacteria, to prioritize such com-
pounds even if the MICs are high (41).
The studies on the mode of action revealed that EN4 affects
bacterial membrane integrity, resulting in a rapid leakage of
ATP. This finding can in part explain its efficacy against sta-
tionary and biofilm bacteria, since the membrane is essential
for both metabolically active and inactive microorganisms.
Many antibiotics target bacterial molecules that are accessible
only in metabolically active bacteria, hindering the eradication
of quiescent pathogens (6, 7). Therefore, the importance of
membrane-active compounds in the eradication of persistent
organisms has recently gained more attention (6). Further-
more, the membranolytic mode of action may prevent the de-
velopment of resistance (41). This was confirmed for EN4 by
several rounds of passages of SA113 in subinhibitory concen-
trations of EN4, where no decrease in susceptibility was ob-
served (data not shown).
The membranolytic multitarget activity is also one of the
attributes of antiseptics. In fact, EN4 exhibits properties similar
to CHX, affecting bacterial membrane integrity and macromo-
lecular biosynthesis, and thereby suggesting an antiseptic-like
character. Both EN4 and CHX (42) are active against Gram-
positive bacteria. EN4 also acts on mycobacteria but, in con-
trast to CHX, not against Gram-negative bacteria. Gram-neg-
ative bacteria are inherently less susceptible to antimicrobials
due to the architecture of the cell wall (30). EN4 acts on Gram-
negative bacteria only upon destabilization of the outer mem-
brane, which further confirms that the membrane is a target
of EN4.
The activity of some antiseptics such as CHX is decreased in
the presence of serum (43). EN4 did not influence SA113 in the
mouse tissue cage model due to inhibition by albumin. Inter-
estingly, another diterpene compound has also failed in vivo
(44). However, this finding has not been further investigated.
The tendency for protein binding and poor tissue distribution
are recognized as an issue of membrane-active agents due to
their general lipophilic character (6). This is well exemplified
by daptomycin, which undergoes organ-specific inhibition by
pulmonary surfactants (45). Furthermore, in contrast to other
membrane-active antibiotics such as daptomycin, oritavancin
(46), or telavancin (47), the cost of membranolytic activity of
EN4 is cytotoxicity on eukaryotic cells, which was also inhib-
ited by serum, suggesting that these properties may be located
at similar sites of the chemical structure of EN4. Nevertheless,
chemical synthesis and structural modifications will be re-
quired to decrease its impairment by albumin and reduce cy-
totoxicity, while retaining antimicrobial properties.
In summary, the present study is a comprehensive investi-
gation of the activity and mode of action of a plant-derived
antimicrobial that impartially evaluates its possible future ap-
FIG 8 Inhibition of activity of EN4 by interaction with albumin. (A) Survival
of SA113 (2! 106 CFU/ml) incubated for 6 h in the presence (gray bars) and
absence (white bar) of EN4 at 100 "g/ml in tryptic soy broth (TSB) supple-
mented with increasing concentrations of tissue cage fluid (TCF), normal hu-
man serum (NHS), human serum albumin (HSA), and human fibrinogen
(hFib). The results were calculated as log10 CFU/ml differences between initial
and final numbers of SA113. The positive values depict growth; the negative
values depict killing. Means# the SDs of three independent experiments are
shown. The dotted line represents a 3-log10 CFU/ml reduction from the initial
inoculum. (B) Cytotoxic effect of EN4 at 100"g/ml on L929 in the presence of
3.75, 5, or 10% FBS investigated over time as described above. The means #
the SDs of three independent experiments prepared in triplicates are shown.
The dotted lines represent the inhibitory concentrations of EN4 causing the
death of 50 or 90% of cells (IC50 and IC90, respectively).
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plications. Due to the good in vitro effect against stationary
growing and biofilm-embedded staphylococci and at the same
time poor in vivo activity, EN4 could serve as a fundamentally
new pharmacophore scaffold for the development of a novel
class of membrane-active compounds to treat biofilm-medi-
ated infections.
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Abstract: The number of implanted medical devices is steadily increasing and has become 
an effective intervention improving life quality, but still carries the risk of infection. These 
infections are mainly caused by biofilm-forming staphylococci that are difficult to treat due to 
the decreased susceptibility to both antibiotics and host defense mechanisms. To understand the 
particular pathogenesis and treatment tolerance of implant-associated infection (IAI) animal 
models that closely resemble human disease are needed. Applications of the tissue cage and 
catheter abscess foreign body infection models in the mouse will be discussed herein. Both 
models allow the investigation of biofilm and virulence of various bacterial species and a 
comprehensive insight into the host response at the same time. They have also been proven to 
serve as very suitable tools to study the anti-adhesive and anti-infective efficacy of different 
biomaterial coatings. The tissue cage model can additionally be used to determine 
pharmacokinetics, efficacy and cytotoxicity of antimicrobial compounds as the tissue cage fluid 
can be aspirated repeatedly without the need to sacrifice the animal. Moreover, with the 
advance in innovative imaging systems in rodents, these models may offer new diagnostic 
measures of infection. In summary, animal foreign body infection models are important tools in 
the development of new antimicrobials against IAI and can help to elucidate the complex 


























Among the early and late complications of medical implants, implant-associated infection (IAI) is one 
of the most serious that is associated with a high morbidity 1. The average rate of IAI ranges between 2% 
to 40% depending on the type of surgical implant 2. These infections occur either perioperatively, by 
direct bacterial contamination during surgery or wound healing, or by the haematogenous route through 
blood or lymph 3. More than 50% of IAI is caused by staphylococci (Staphylococcus (S.) aureus and S. 
epidermidis), followed by streptococci (7%) and Propionibacterium spp. (6%). Gram-negative bacilli, 
enterococci and polymicrobial infections are less frequent (less than 5 % each) 3,4. Over the last four 
decades methicillin resistant S. aureus (MRSA) has created additional therapeutical challenges. 
Importantly, it has been estimated that in a high endemicity setting more than half of surgical-site 
infections due to staphylococci can be caused by MRSA 5. 
An important feature of IAI is that the presence of a foreign body increases the susceptibility to 
staphylococcal infection by at least 10,000-fold 6,7. Hence, these infections can arise from only a few 
bacteria inoculated locally during surgery or during bacteraemia. They remain local, but if infection 
becomes chronic, the implant has to be removed or replaced for healing. 
The main reason for persistence of IAI is the microbial ability to form biofilm. Staphylococci use 
biofilm as a dynamic survival strategy, which decreases their susceptibility to both antimicrobials and host 
response. As the decreased antimicrobial susceptibility is not driven by acquisition of any resistance genes 
and biofilm-embedded bacteria are isogenic with their planktonic antibiotic-susceptible counterparts this 
phenomenon is referred to as bacterial tolerance. Indeed, proteomic and RNA profiling studies have 
shown altered gene expression patterns in staphylococcal biofilms, indicating metabolic adaptation 8. 
Although the molecular details of biofilm development have been thoroughly investigated, the exact 
mechanism of its antimicrobial tolerance remains still elusive. Biofilm allows bacteria to stay in a 
metabolically quiescent state as a multilayered community embedded in a self-produced extracellular 
matrix. The matrix can be composed of polysaccharide intercellular adhesin (PIA), the production of 
which is mediated by the ica-locus encoded enzymes, of fibronectin-binding protein and other large 
proteins, and of extracellular DNA, which is released by bacterial lysis 9. The expression of these 
components is governed by four major transcriptional regulators, which are the quorum sensing systems 
agr and luxS as well as sarA and the stress sigma factor sB. They interact in a complex network and have 




















contribute as well to the formation, maturation and dispersal of biofilms 9,10.  Agr-regulated phenol-soluble 
modulins (PSM) are of particular importance in structuring and detachment of staphylococcal biofilm and 
thereby facilitate bacterial dissemination. Thus, PSM have recently been postulated as potential target for 
the treatment of S. aureus infections 11,12. 
As a consequence of the biofilm-induced bacterial tolerance antimicrobial treatment of IAI remains 
challenging. To overcome this tolerance, antimicrobials need to penetrate the biofilm and act on adherent 
stationary-phase bacteria. Of note, some antibiotics, e.g. vancomycin and daptomycin, are able to 
penetrate the biofilm but eventually fail to eradicate the adherent bacteria 13,14. So far, most of the known 
antibiotics are dependent on the metabolic status of bacteria hindering the eradication of biofilm-
embedded quiescent pathogens. The only antibiotic with a proven activity against metabolically inactive 
staphylococci in IAI is rifampicin 15. However, due to a rapid emergence of resistance, rifampicin has to 
be combined with other antibiotics 16,17. The emergence of resistant bacteria (i.e. MRSA and methicillin 
resistant S. epidermidis) creates additional challenges, as resistance is associated with a poorer response to 
therapy. Thus, antimicrobial therapy of biofilm-mediated infections is often unsuccessful unless the 
biofilm is removed by surgical debridement 16. Therefore, novel anti-biofilm agents, such as the 
acyldepsipeptide  (ADEP4) 18, as well as antifouling and antimicrobial implant coatings19 are under 
investigation.  
A further important reason for the persistence of staphylococcal biofilm on foreign bodies is its 
recalcitrance to host immune responses 20. Contact with implant surface induces impaired granulocyte 
functions, including reduced bactericidal activity, impaired oxidative metabolism and spontaneous 
granular enzyme release 21,22. Interestingly, human PMNs recovered from patients with osteomyelitis 
exhibited highly activated phenotype with preserved production of superoxide but impaired chemotactic 
abilities 23,24. Moreover, biofilm burden seems to be also dependent on macrophage proinflammatory 
responses highlighting mutual influence between host cells and biofilm 25. 
Taken together, IAI belongs to the leading infections in today’s medicine. To better understand the 
biofilm antimicrobial tolerance, host response and molecular pathogenesis as well as to develop effective 
antimicrobials for these infections adequate animal models are needed. Depending on the question to 
study, different foreign body infection models can be used.  
2.  Orthopaedic Implant Infection Models 
There are various orthopaedic animal models for investigation of IAI. Many of them involve insertion 
of implants into bones of the lower limb. They are suitable for studies of materials and their interactions 
with the bone tissue. The most recent models use bacteria-loaded pins inserted into the mouse tibia 26 or 
bacteria-loaded holes drilled with screws in the rabbit femur 27. Other models in rabbits and sheep 




















compression plate 29, respectively. All these models were recently comprehensively described 19 and are 
beyond the scope of this review. The differences between the orthopaedic and the subcutaneous foreign 
body models described here are summarised in Table 1. Orthopaedic models allow imaging, 
bacteriological and histological analyses only after sacrifice. They are not suitable for multiple sampling 
to test antimicrobial activity, pharmacokinetics and to investigate the immune response. Furthermore, 
these models often require sophisticated surgical techniques and high numbers of large animals in order to 
determine the time course of infection.  
A recent study has overcome these drawbacks by using a genetically engineered mouse strain with 
fluorescent myeloid cells and infection with bioluminescent staphylococci. The authors inoculated the 
knee joints after placement of a wire implant into the mouse femur. They determined the quantity and 
localisation of both bacteria and neutrophils noninvasively and longitudinally by 3D fluorescence and 
bioluminescence imaging and they assessed the anatomical bone changes using micro-computed 
tomography registration. However, the advanced equipment required for analysis does not yet allow 
application of this method in practice to various animal species and bacterial clinical isolates 30.  
In summary, IAI models in bone are of a great interest, as they closely mirror the clinical situation of 
bone-inserted implants. Nevertheless until today they are technically difficult and do not allow an easy 
assessment of the antibacterial effect and host immune response.  
However, subcutaneous foreign body models such as the tissue cage and the catheter model can well 
simulate extravascular IAI in human settings 22. They additionally allow accurate analysis of planktonic 
and adherent bacteria, therapeutic efficacy and host responses. Moreover, these models can easily be 
applied to study implants of various materials, their interactions with the host immune system and with the 
bacteria over time without the need to sacrifice an animal. Both models can be used in guinea pigs, rats 
and mice. Their application, advantages and disadvantages are described below.  
3. Tissue Cage Infection Model  
3.1.Tissue cage model in different animal species 
The tissue cage model was first described by Zimmerli in 1982 7. He established the short-term 
antibiotic therapy of staphylococcal foreign body infection in guinea pigs 31,32 and was the first to observe 
the granulocyte defects at the site of a foreign body 21.  Since then guinea pigs have been proven as a 
suitable model for therapeutic studies of IAI 15,33-35. Guinea pigs present the advantage of a high 
susceptibility to staphylococcal infection, the infection remains strictly local and pharmaco-dynamics and 
-kinetics of humans can be simulated 36 (Table 1). A drawback is the intolerance of guinea pigs to 
prolonged antibiotic treatment as well as to betalactams 36. Although rats tolerate these antibiotic 




















applied, a high proportion of these animals spontaneously clear staphylococcal implant infection 37. The 
availability of genetically engineered mice, their susceptibility to staphylococcal infection and their 
tolerance to antibiotics, the easy manufacturing of genetically modified bacteria and advanced animal 
imaging facilities, allowed mice to become an attractive alternative to study pathogenesis and therapy of 
IAI using tissue cages.  
3.2.  Tissue cage infection model in the mouse  
3.2.1. Technique 
Cylindrical tissue cages (8.5 × 1 × 30 mm, volume 1.9 mL) 36 are manufactured from Teflon or from 
any type of metal or alloy 38. The wall of each cage is perforated with 130 regularly spaced 1.0-mm holes. 
A hole of 2 mm in diameter is placed both in the Teflon lid and in the bottom of the cage. To increase the 
surface area, cages can be filled with beads from sinter glass or from any material. Cages are implanted 
subcutaneously into the back of anesthetized 12- to 15-week-old C57BL/6 mice (Figure 1 a, b). Bacteria 
are injected directly into the cage either perioperatively or around 14 days postoperatively. In contrast to 
guinea pigs, S. epidermidis should be injected only peri-operatively as it can be spontaneously cleared if 
injected postoperatively 38. S. aureus needs to be injected post-operatively after wound healing to avoid 
the risk of surgical site infections with deep abscesses. Sterility before infection and the establishment of 
an infection are confirmed by quantitative culture of tissue cage fluid (TCF). The infection with and 
without subsequent therapy is usually followed for 14 days, however mice tolerate as well a prolonged 
infection and antimicrobial treatment without systemic signs (unpublished data). The inflammation 
remains localized and animals in general do not develop bacteraemia. 
The load of planktonic bacteria and the local host immune response to infection are assessed by 
repetitive puncture of TCF (Figure 1. c). TCF resembles the extracellular fluid with about 50% of the 
serum protein concentration, similarly to noninflammatory interstitial fluid 7. Antimicrobials can be either 
injected directly into the cage or applied by all other routes (intraperitoneally (i.p.), subcutaneously, 
orally, intravenously). The efficacy of antimicrobial treatment is monitored on planktonic bacteria in TCF 
and on implant-associated microorganisms after explantation. Several applications of the mouse tissue 
cage model are described below. 
3.2.2. Assessment of virulence of bacterial species 
The inoculum necessary for induction of a persistent infection in tissue cages of C57BL/6 mice is 
assessed by identifying the minimal infective dose (MID) of the investigated bacterial species or strains. 
The MID is an indicator of staphylococcal virulence in this model. For S. aureus it ranges between 




















is much higher, namely above 106 CFU/cage, and spontaneous healing occurs, if bacteria are not injected 
during the perioperative period 38. In infections with isogenic mutants of staphylococci, which have 
specific deletions of virulence genes, a higher MID may be required. This was for example shown for the 
S. aureus dlt- mutant, which manifested a 100-fold higher MID than the parental wild type (wt) strain. 
This mutant expresses non-alanylated lipoteichoic acid, which renders the surface charge of the bacterial 
cell wall more negative, and thus more susceptible to cationic antimicrobial peptides. Therefore, the dlt- 
mutant is more easily cleared unless the infective dose is increased 40. On the other hand, the virulence of 
S. aureus mutants lacking the ica gene responsible for polysaccharide-mediated biofilm formation, has not 
been attenuated in the tissue cage model 41. Even in competitive infection studies with simultaneous 
inoculation of both wt and ica- S. aureus, the ica mutant did not grow less efficiently than the wt 42.  These 
observations were surprising, since ica expression is considered one of the crucial contributors to 
staphylococcal biofilm, which is generally considered as the major virulence factor in IAI. Indeed, in 
contrast to the S. aureus counterpart, ica mutants of S. epidermidis, , showed reduced virulence in the 
tissue cage model 42 and in catheter-associated infections both in rats 43 and in mice in our own studies 
38,44. Thus, our results illustrate that conclusions on virulence in IAI models can only be applied to the 
particular bacterial species and the exact model used in the given investigation, i.e. for S. epidermidis 
biofilm plays a more significant role in virulence than for S. aureus, which has multiple factors mediating 
adherence 45,46. 
The tissue cage can be considered as a closed in vivo system, in which any bacterial species is exposed 
to host phagocytes. In that context the model has been shown to be suitable to assess the role of a sialidase 
in Capnocytophaga canimorsus in vivo. This commensal bacterium was shown to survive in vitro only in 
the presence of human cells, where it could feed on host glycoproteins using its surface-exposed sialidase. 
This behaviour could also be demonstrated by infection with wt but not with sialidase-deficient bacteria in 
normal and leukocyte-depleted tissue cages 47. 
Another interesting feature to study biofilm in vivo is to combine it with bioluminescence imaging.  A 
chromosomally expressed lux operon in S. aureus renders bacteria visible in a CCD camera and allows 
close observation of the bacterial load during infection 48. A more sophisticated application of this 
technique is to follow promoter activity of a virulence factor in S. aureus. For this aim we transduced a 
specific promoter-regulated lux operon into wt or isogenic mutant of S. aureus 49. We could demonstrate 
an increasing activity of the hla promoter during eight days of a tissue cage infection and its modulation 
by transcriptional regulators sB and sae 49 (Figure 2). Nevertheless, the targeted bioluminescence is 
limited by its relatively low sensitivity due to the single copy of the gene in question.  




















TCF is an extracellular fluid containing myeloid cells as innate defense system. Strikingly, 
granulocytes in the neighbourhood of a tissue cage display weakened functions, including bactericidal 
activity, oxygen burst, phagocytosis and spontaneous loss of granules 21. To investigate in depth the role 
of leukocyte subpopulations in the defense against tissue cage infections, experiments in leukocyte- or 
granulocyte-depleted mice can be performed. Furthermore, the mechanisms of host defense in this 
infection model can also be unravelled in knockout mouse strains with specific deficiencies of the innate 
immune system. As an example, we could show that dlt- bacteria, which were cleared in wt mice, 
proliferated in TLR2-deficient host, thus identifying a role of TLR2 in murine immune defense against 
bacteria expressing unalanylated teichoic acids 40. 
3.2.4. Assessment of antibiotic resistance in vivo 
Little is known about the evolution of antibiotic resistant staphylococci during an infection. The tissue 
cage model provides the opportunity to investigate an antibiotic-resistant staphylococcal strain during the 
course of infection over a prolonged period of time (two to four weeks). Stability of genetic and 
phenotypic changes, which characterize the resistance, can be repeatedly evaluated in the treated or 
untreated tissue cage. This approach was used to investigate glycopeptide (teicoplanin)-intermediate 
resistance in S. aureus (GISA). This resistance arises from prolonged glycopeptide exposure and is the 
result of multiple unknown mutations leading to a common phenotype of GISA. Gene expression and 
phenotype were followed in isogenic GISA and wt strains without antibiotics in the tissue cage. 
Interestingly, teicoplanin resistance posed a fitness burden on S. aureus, which resulted in a negative 
selection in vivo with restoration of fitness incurring the price of resistance loss 50. 
3.2.5. Pharmacokinetic (PK) studies  
Small, cost-effective pre-development of in vivo PK and toxicity studies can be done in the mouse 
tissue cage model with minimal compound requirement and multiple endpoints. New compounds, which 
have poor in vivo PK profiles, can be injected directly into the cage. Better defined more advanced 
compound series can be assessed for their potency after intraperitoneal administration.  
The goal of antibiotic treatment studies in animals is to mimic the conditions in humans. Therefore, PK 
of the drugs has to be adapted to those in humans. So far, PKs in our mouse tissue cage model have been 
determined for daptomycin with 30 mg/kg 13, 40 mg/kg 13 and 50 mg/kg 51 applied i.p. once per day 13, 
vancomycin 150 mg/kg three times per day and levofloxacin 150 mg/kg three times per day (unpublished 
results). For every antibiotic, TCF is taken at time points 0, 30 min, 60 min, 2 h, 4 h, 6 h, 8 h, 12 h and 24 




















to reach Cmax (Tmax), the trough (minimum) concentration at 24 h after dosing (Cmin), the half-life (t1/2), and 
the area under the curve over a specific time (AUC0-24) can be calculated.  
3.2.6. Pharmacodynamic properties and efficacy 
While many in vitro tests can give hints on antimicrobial properties of new drugs, mouse models have 
been developed in order to assess their efficacy in vivo. This is of great interest, since in vivo and in vitro 
results of transcriptional regulator were found to differ 42,52. Growth curves, minimal inhibitory and 
bactericidal concentrations (MIC and MBC, respectively) of each antibiotic are determined beforehand for 
all bacterial strains. For therapeutic studies, infected mice are treated with saline (control group) or the 
respective antibiotic dosage for three to four days. On day four, TCF is collected to quantify planktonic 
bacteria and the animals are sacrificed. Tissue cages are removed under aseptic conditions and incubated 
in broth for 48 h, followed by assessment of bacterial growth. A positive culture is defined as a treatment 
failure. The efficacy of treatment against adherent bacteria is expressed as the cure rate (in percent), 
defined as the number of cages without growth divided by the total number of cages in the individual 
treatment group. Depending on the type of antibiotic used, to avoid the carry-over effect and false 
negative culture animals can be kept more than four day after drug withdrawal. Using this procedure, it 
became evident that daptomycin is not efficacious against adherent bacteria. The tolerance of adherent S. 
aureus to daptomycin was not related to biofilm, but was likely due to enhanced membrane stability 
during adherence and could be reverted by addition of Ca2+ ions 13.  
In a recent study, we investigated the antimicrobial activity and mode of action of a serrulatane 
compound, 8-hydroxyserrulat-14-en-19-oic acid (EN4), a diterpene isolated from the Australian plant 
Eremophila neglecta. In vitro EN4 elicited antimicrobial activity toward various Gram-positive bacteria in 
logarithmic, stationary growth phase and embedded in biofilm. Additionally, EN4 was also cytotoxic 
against eukaryotic cells. In vivo however neither bactericidal nor cytotoxic effects were present, indicating 
an inhibition of its activity. Inhibition assays revealed that this was caused by interaction of EN4 with 
albumin 39.  
3.2.7. Cytotoxicity of new antimicrobial compounds against host cells  
In the evaluation of new anti-infective compounds, the therapeutic window is an early predictor of 
success or failure in drug development. Leukocyte viability in the tissue cage is an indicator of in vivo 
drug cytotoxicity. Mechanistic aspects of eukaryotic cell death can be distinguished ex vivo by flow 
cytometric analysis of apoptosis and necrosis. The evaluation of efficacy and at the same time toxicity 
from one sample is particularly important for compounds with the same mechanism of action on 




















antibacterial compounds, block respiratory enzymes both in human cells and in bacteria. Thus, the 
therapeutic window is likely very small and the silver concentration the eukaryotic cells are exposed to 
must be limited e.g. by applying slow-release compounds. We have tested in vivo the bactericidal activity 
of silver coordination polymers coated on titanium cages. Indeed, the bactericidal activity on planktonic S. 
epidermidis was paralleled by a transient decrease in leukocyte viability in the cage 53. However, 
histological investigation of the surrounding tissue of silver-coated cages including the capsule and the 
muscle did not show increased inflammation or necrosis compared to uncoated cages (Fromm K. and 
Khanna N., unpublished data).  
3.2.8. Properties of different tissue cage materials 
Tissue cages can be manufactured from Teflon, ceramics or any metal or alloy. We found that the 
metal titanium or steel played a minor role in propensity to biofilm generation or in persistence of 
staphylococcal infection 38.  
4.  Catheter Abscess Model 
Another model of IAI is a static subcutaneous catheter abscess model in which, contrary to the tissue 
cage model, a systemic infection may develop due to an unrestricted blood flow and inflammatory cell 
recruitment. In that model bacteria are either precultured overnight with the catheter in vitro to form 
biofilm or bacteria are added when the catheter is implanted into subcutaneous tissue in the flank of 10- to 
14-week old mice (Figure 3). An abscess formation occurs, which can be quantified by the oedema cross-
section dimension. Infection with a high inoculum of virulent S. aureus strains leads to bacteremia and 
sepsis and is not advised with this model. Animals have to be sacrificed at different time points for further 
analysis. Bacteria that are adherent to the catheter or present in the tissue surrounding the catheter are 
quantified one to eight weeks after infection. The cytotoxicity of investigated compound can be assessed 
by analysis of the subcutaneous tissue around the implant.  
Various catheter models have been used by other groups to study IAI. In a central venous 43 and a 
subcutaneous catheter in the rat 44 S. epidermidis infections occurred more often with a biofilm-ica-
positive than with a biofilm-negative strain. In a study on infection with a bioluminescent S. aureus the 
efficacy of a 4-day rifampicin treatment upon an established biofilm was well documented with this 
noninvasive method 54. 
We used the catheter model to study the mechanism, by which biofilm protects S. epidermidis from 
clearance by host defense. The complement component 3 (C3) activation and C3b/IgG deposition on S. 
epidermidis as well as granulocyte-dependent killing of wt and ica- bacteria were compared. We found an 




















findings correlated with a stronger survival of wt S. epidermidis on catheters 20. This is the first 
observation regarding the molecular pathophysiology of host defense against biofilm. Importantly, the 
host response to catheter infection can differ from the tissue cage, as the recruitment of neutrophils to the 
catheter can be limited due to the low number of planktonic bacteria 55.  Indeed, macrophages, but not 
neutrophils, have recently been shown to play an important role in the controlling of staphylococcal 
biofilm in the catheter infection model 25. 
The catheter model is also suitable to study biofilm in other bacteria such as Pseudomonas aeruginosa. 
The role of cyclic di-GMP regulation in small colony variant (SCV) formation, biofilm production and 
persistence was investigated with mutants overexpressing a diguanylate cyclase YfiN, responsible for the 
SCV phenotype. Both in single and competitive catheter infections wt bacteria were found to be less 
persistent after eight weeks despite an initial growth advantage 56.  
Altogether, there are numerous applications of the catheter model. In contrast to the tissue cage, 
inflammation is not localised within the device, but can also induce systemic infection. Toxicity of 
antibacterial substances can be assessed in the surrounding tissue, which contains, similarly to the tissue 
cage model, immune and stromal cells.  
5. Disadvantages of subcutaneous animal foreign body models 
Despite the advantages of these models, they also have some limitations. With the tissue cage and 
catheter model, only general aspects of host response and biocompatibility can be analyzed. However, 
specific problems related to bone implants, vascular grafts or neurosurgical devices cannot be studied.  In 
addition, for pharmacokinetic and pharmacodynamic studies, the special situation of metabolic processes 
in small animals as compared to humans has to be considered. 
6. Conclusions 
The two described subcutaneous IAI models are well-established long-standing in vivo models in 
which microbiological, pharmacological, immunological, and chemical properties of biomedical implants 
can be assessed. Both models are easy to perform. Up to 20 animals can be implanted, infected and treated 
daily by one person. Subcutaneous tissue cages or catheters are well tolerated by mice, even for prolonged 
periods exceeding one month. The particular advantage of the tissue cage model is the closed system that 
allows the repeated assessment of the interactions between antimicrobials, host responses and biofilm-
forming bacteria in vivo. The fact that the cages can be manufactured from any material, which is used in 
orthopaedic implants, makes the model relevant for pre-clinical application. The cages can be coated with 
any new compound as local anti-infective or anti-adhesive substance to prevent IAI. The particular 




















various Gram-positive and Gram-negative bacteria. Current and future work focuses on the development 
of implant surfaces with covalently coated or triggered-release antimicrobials to prevent IAI and on new 
compounds that inhibit the formation of biofilm. 
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Figure 1. (a) Teflon cage with glass sinter beads.  (b) Mouse ten days after implantation. (c) Aspiration of 




























Figure 2. Visualization of S. aureus hla- promoter activity using luxABCD integration vector. The 
phla-lux construct was introduced via a single chromosomal insertion in the S. aureus wt strain Newman 
and its isogenic sae and sB regulator mutants. Hla-expression was followed in real-time at repeated time 
points of infection (here day eight) of a mouse tissue cage using a photon-sensitive camera. The activation 
of hla in the sB-deficient strain and the repression to background levels in a sae-deficient strain relative to 




Measuring of bioluminescence during in vitro growth
The luminescence of strains Newman pAS2 and
Newman Xen 29 was first followed during in vitro
culture in liquid media. No growth difference, measured
as OD, was observed between both strains. The
luminescent signal was 2–3 log10 higher in Newman
Xen 29 than in Newman pAS2. The luminescence
signals increased until 5 h (Newman Xen 29) or 6 h
(Newman pAS2) of growth after which the signal
decreased in both strains. Previously, the effect of a
rapid decline of luciferase activity was described in
E. coli expressing luxAB of Vibrio fischeri under the
control of a consensus-type promoter (Koga et al.,
2005). The authors speculate that this effect was due to
the depletion of FMNH2, the direct electron donor for
the bacterial luciferase reaction, and the activity of a
regulatory process controlling the redox state of the
bacterial cell. This finding was confirmed by another
group (Galluzzi and Karp, 2007), who reported an
important role of the intracellular redox state and the
growth phase on the overall response of bacteria serving
as whole-cell biosensors based on the bacterial luciferase
operon. Thus, at least in vitro the bioluminescence
signal during stationary phase is rather correlated to the
metabolic than to the promoter activity, which shows
one limit of this approach.
Influence of antibiotics on hla expression
Next we assayed the influence of antibiotics on
luciferase activity on agar plates. An activating effect
of subinhibitory concentrations of the beta-lactam
ant biotic imipenem on the hla promoter, result ng in a
strong luminescent signal in th c lonies directly
bordering the inhibition zone (Fig. 1) could be detected.
This is accordance wit previous reports on enhanced
hemoly ic activity due to beta-lactam antibiotics using
different detection meth ds (Gemmell, 1995; Lorian,
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Fig. 2. (A) Mice with implanted tissue-cages were infected with one of the test strains of S. aureus and imaged using the IVIS
imaging system during 8 days of infection. Left panel: bioluminescent signals of S. aureus Newman pAS2 (filled circles), Newman
sigB pAS2 (triangles), Newman sae pAS2 (squares), Newman Xen 29 (diamonds; positive control), and Newman pAS3 (open circles;
negative control). Mean values and standard errors of 5–8 mice per group from repeated experiments. Right panel: one mouse per
group photographed on day 8 of infection. The variations in color represent the intensity of luminescence at the given location, with
red corresponding to the strongest signal. The amplification scales of the photons/s/cm2 are indicated below the pictures. (B) CFU
per ml of tissue-cage fluid during infection. Mean values and standard errors of 5–8 mice per group from repeated experiments.












































Table 1. Comparisons of orthopaedic and subcutaneous foreign body infection models. 






Animal species rabbit/ sheep/ rat/ 
mouse/ guinea pig/ 
chicken/ dog/ pig/goat  
guinea pig rat mouse mouse 19,57 
Labour intensity +++ ++ ++ ++ + 36,58 
Large scale experiments no nd nd yes yes 59,60 





species-dependent yes no yes yes 19,36,57 
Antibiotic tolerance 
(long-term treatment) 
species-dependent no yes yes yes 36 
Use of transgenic animals nd nd nd yes yes 40 
Imaging yes nd yes yes yes 19,28,30,49,6
1-66 
Bacterial virulence factors only after sacrifice yes no yes yes 19,40-
43,56,67-76 
Host immune response yes yes yes yes yes 20,21,25,30,5
9,62,65,77-80 
Osseointegration yes no no no no 19 
Various implant 
materials/coatings 





Cytotoxicity on eukaryotic 
cells 
no nd nd yes no 39,53 
Pharmacokinetics (PK) at 
the infection site 
no yes yes yes no 7,13,36 
Pharmacodynamics (PD) no yes yes yes no 13,17,19,39,8
4-88 
Similarity to human 
disease: 
 
Localised infection yes yes yes yes no this 
review, 
19,36 
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